Targretin Is Second Product In Ligand CTCL Therapy Triple Offering
Executive Summary
The approval of Targretin capsules is the second step in Ligand's plan to offer patients with cutaneous T-cell lymphoma treatment options for all stages of the disease. The company currently markets Ontak and recently submitted an NDA for Targretin Gel.
You may also be interested in...
Merck Re-Enters Oncology With Zolinza Approval For Rare Skin Cancer
Merck's oncologic Zolinza will be available mid-October at a cost of $60 per capsule, the company said following vorinostat's Oct. 6 approval for a rare skin cancer.
Merck Re-Enters Oncology With Zolinza Approval For Rare Skin Cancer
Merck's oncologic Zolinza will be available mid-October at a cost of $60 per capsule, the company said following vorinostat's Oct. 6 approval for a rare skin cancer.
Ligand Expects First Of Two Osteoporosis SERM Launches As Early As 2002
Ligand collaborator Pfizer could launch the first of the company's selective estrogen receptor modulators for osteoporosis as early as 2002, the company told analysts March 20.